Source comparison
TB-500 Meniscus Injury Mechanism: Comparison Analysis
Primary Target G-actin sequestration for cell migration VEGF upregulation for angiogenesis COX enzyme inhibition to reduce prostaglandins TB-500 addresses cell logistics; BPC-157 addresses vascular supply; NSAIDs suppress symptoms but delay repair Optimal Timi
This comparison does not assign a generated winner or score.
- Primary Target
- G-actin sequestration for cell migration
- VEGF upregulation for angiogenesis
- COX enzyme inhibition to reduce prostaglandins
- TB-500 addresses cell logistics; BPC-157 addresses vascular supply; NSAIDs suppress symptoms but delay repair
- Optimal Timing Window
- Days 0–14 post-injury (migration phase)
- Days 3–21 post-injury (proliferation phase)
- Days 0–7 (acute inflammation only)
- Sequential use may be optimal: TB-500 early, BPC-157 mid-phase, NSAIDs sparingly if at all
- Tissue Type Efficacy
- Highest in vascularized tissue (red zone meniscus)
- Moderate across all zones (stimulates new vessel formation)
- Symptom relief only; no tissue repair component
- Vascular status is the determining factor. White zone tears unlikely to respond to either peptide alone
- Mechanism Evidence Base
- Preclinical rodent models; no human RCTs
- Preclinical models + limited human case series
- Extensive human data (symptom reduction proven; repair inhibition also proven)
- TB-500 mechanism is well-characterized at cellular level but lacks clinical-grade human efficacy data
- Dosing Frequency
- Every 3–4 days (matches 48–72h half-life)
- Daily or twice-daily (shorter half-life, ~4–6h)
- As-needed or scheduled (symptom-driven)
- Frequency must match peptide pharmacokinetics. Daily TB-500 dosing is cost-inefficient without added benefit